Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Income from Non-Controlling Interests of $2588.0 for Q1 2026, up 129.13% on a YoY basis from $1129.5 in Q1 2025, and up 115.27% sequentially from -$16950.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 17 years of Income from Non-Controlling Interests data on file, last reported at $2588.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 129.13% year-over-year to $2588.0; the trailing twelve-month figure through Mar 2026 stood at -$17111.0 (down 2.95% YoY), and the FY2025 full-year result was -$28583.0, down 179.28% from the prior year.
- Income from Non-Controlling Interests grew to $2588.0 in Q1 2026, from -$16950.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $43791.0 in Q1 2024 to a low of -$29046.0 in Q2 2022.
- A 5-year average of -$7128.5 and a median of -$10046.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests jumped 320.08% in 2024 and plunged 878.59% in 2025, its largest moves.
- Tracing CPIX's Income from Non-Controlling Interests over 5 years: stood at -$18985.0 in 2022, then soared by 60.07% to -$7581.0 in 2023, then soared by 128.72% to $2177.0 in 2024, then sank by 878.59% to -$16950.0 in 2025, then soared by 115.27% to $2588.0 in 2026.
- Business Quant data shows CPIX's Income from Non-Controlling Interests at $2588.0 in Q1 2026, -$16950.0 in Q4 2025, and -$8282.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn | 2,588.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,588.00 |
| Dec 31, 2025 | -16,950.00 |
| Sep 30, 2025 | -8,282.00 |
| Jun 30, 2025 | 5,533.00 |
| Mar 31, 2025 | -8,884.00 |
| Dec 31, 2024 | 2,177.00 |
| Sep 30, 2024 | 7,112.00 |
| Jun 30, 2024 | -17,025.00 |
| Mar 31, 2024 | 43,791.00 |
| Dec 31, 2023 | -7,581.00 |
| Sep 30, 2023 | -13,921.00 |
| Jun 30, 2023 | -10,046.00 |
| Mar 31, 2023 | -19,898.00 |
| Dec 31, 2022 | -18,985.00 |
| Sep 30, 2022 | -14,587.00 |
| Jun 30, 2022 | -29,046.00 |
| Mar 31, 2022 | -17,180.00 |
| Dec 31, 2021 | -36,561.00 |
| Sep 30, 2021 | -31,415.00 |
| Jun 30, 2021 | -5,069.00 |